Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). The EGFR-T790M secondary mutation is responsible for half of acquired resistance cases, while MET amplification has been associated with acquired resistance in about 5-15% of NSCLCs. Clinical findings indicate the retained addiction of resistant tumors on EGFR signaling. Therefore, we evaluated the molecular mechanisms supporting the therapeutic potential of gefitinib maintenance in the HCC827 GR5 NSCLC cell line harbouring MET amplification as acquired resistance mechanism. We demonstrated that resistant cells can proliferate and s...
Lung adenocarcinoma cells harboring epidermal growth factor receptor (EGFR) mutations are sensitive ...
Introduction: Development of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase i...
To study epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance mechanisms...
Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-s...
Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-s...
Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-s...
Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-s...
Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-s...
Non-small cell lung cancers (NSCLCs) with activating mutations in the kinase domain of the epidermal...
Background: MET amplification has been detected in ∼20% of non-small-cell lung cancer patients (NSCL...
Abstract Background Epidermal growth factor receptor ...
IntroductionMesenchymal status is related to “inherent resistance” to gefitinib or erlotinib in non-...
AbstractAlthough cancers can be initially treated with the epidermal growth factor receptor (EGFR) i...
Introduction: Development of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase i...
Introduction: Development of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase i...
Lung adenocarcinoma cells harboring epidermal growth factor receptor (EGFR) mutations are sensitive ...
Introduction: Development of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase i...
To study epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance mechanisms...
Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-s...
Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-s...
Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-s...
Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-s...
Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-s...
Non-small cell lung cancers (NSCLCs) with activating mutations in the kinase domain of the epidermal...
Background: MET amplification has been detected in ∼20% of non-small-cell lung cancer patients (NSCL...
Abstract Background Epidermal growth factor receptor ...
IntroductionMesenchymal status is related to “inherent resistance” to gefitinib or erlotinib in non-...
AbstractAlthough cancers can be initially treated with the epidermal growth factor receptor (EGFR) i...
Introduction: Development of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase i...
Introduction: Development of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase i...
Lung adenocarcinoma cells harboring epidermal growth factor receptor (EGFR) mutations are sensitive ...
Introduction: Development of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase i...
To study epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance mechanisms...